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ABSTRACT 
 
Huntington’s disease (HD) is the most common of nine inherited neurological disorders 
caused by expanded-polyglutamine (polyQ) sequences which confer propensity to self-
aggregate and toxicity to their corresponding mutant-proteins. It has been postulated 
that polyQ-expression compromises the folding capacity of the cell which might affect 
other misfolding prone proteins. α-Synuclein (α-syn) is a small neural-specific protein 
with propensity to self-aggregate that forms Parkinson’s disease (PD) Lewy bodies. 
Point mutations in α-syn that favor self-aggregation or α-syn gene duplications lead to 
familial-PD, thus indicating that increased α-syn aggregation or levels are sufficient to 
induce neurodegeneration. Since polyQ-inclusions in HD and other polyQ-disorders are 
immunopositive for α-syn, we speculated that α-syn might be recruited as an additional 
mediator of polyQ-toxicity. Here we confirm in HD postmortem brains and in the R6/1 
mouse model of HD the accumulation of α-syn in polyQ-inclusions. By isolating the 
characteristic filaments formed by aggregation prone proteins, we found that N-terminal 
mutant huntingtin (N-mutHtt) and α-syn form independent filamentous microaggregates 
in R6/1 mouse brain as well as in the inducible HD94 mouse model, and that N-mutHtt 
expression increases the load of α-syn filaments. Accordingly, α-syn knock-out results 
in diminished number of N-mutHtt inclusions in transfected neurons and also in vivo in 
the brain of HD mice. Finally, α-syn knock-out attenuates body-weight loss and early 
motor phenotype of HD mice. This study therefore demonstrates that α-syn is a modifier 
of polyQ-toxicity in vivo and raises the possibility that potential PD-related therapies 
aimed to counteract α-syn-toxicity might help to slow HD. 
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INTRODUCTION 
 
Huntington’s disease (HD) is the most common of a group of nine inherited devastating 
neurological disorders caused by CAG triplet-repeat expansions encoding expanded 
polyglutamine (polyQ) sequences which in turn confer toxicity to their mutated protein 
products (1). In HD, this expanded polyQ stretch is located in the N-terminal portion of 
the huntingtin (Htt) protein (2). A shared feature of polyQ diseases is the presence of 
nuclear and cytoplasmic intraneuronal inclusion bodies consisting primarily of 
aggregation-prone polyQ proteins (3, 4). The exact mechanism by which expanded 
polyQ induces neurodegeneration remains unknown. However, it has been suggested 
that progressive disruption of protein folding machinery of the cell might explain the 
commonalities among the neurodegenerative diseases associated with chronic 
expression of misfolded and aggregation prone-proteins (5). 
 
α-Synuclein (α-syn) is a small neural-specific protein involved in synaptic function  (6, 
7) with propensity to self-aggregate (8). α-Syn has been implicated in the etiology of 
Parkinson’s disease (PD) as well as of other neurodegenerative diseases such as 
multiple system atrophy and Lewy body dementia that share the presence of the 
characteristic cytoplasmic inclusions termed Lewy bodies (9). The notion of α-syn as a 
pathogenic protein arises from, in one hand, the fact that α-syn is the main component 
of Lewy bodies (9, 10) . On the other hand, point mutations in α-syn that confer a higher 
propensity for self-aggregation (11, 12) are linked to autosomal-dominant forms of PD 
(13-15) and duplication and triplication of the α-syn gene lead to a severe and highly 
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penetrant form of PD (16). Collectively, these findings highlight the ability α-syn to 
induce or cause neurodegeneration.  
 
It has been reported that α-syn can also be detected in the inclusions of HD patients (17) 
and of patients of other CAG repeat disorders such as SCA-2 and SCA-3 (18, 19). The 
same holds true for the inclusions of the HD89 mouse model of HD (17). Furthermore, 
there is evidence that α-syn may act as a modifier of polyQ toxicity in cell and 
Drosophila models of HD. Namely, α-syn overexpression promotes aggregation of 
mutant Htt in PC12 and  SKNSH neuroblastoma cells (20, 21), and neuronal expression 
of α-syn increases neurodegeneration of flies expressing exon-1 Q120 Htt in eyes (21). 
 
Given the well-established pathogenicity of α-syn alterations, the accumulation of α-syn 
in inclusions of HD mice and patients and the crosstalk between α-syn and mutant Htt in 
cell and fly HD models, we reasoned that in the context of mutant Htt-induced disease, 
α-syn might be recruited as an additional mediator of toxicity. Here we aim to take 
advantage of mouse genetics to explore this. Accordingly, here we first confirm the 
presence of α-syn in cytoplasmic inclusions in brain of HD patients and extend this 
finding to the commonly used R6/1 mouse model of HD (22). Then, by applying a 
previously reported method (23) to isolate from mouse brain the filaments made of 
aggregation prone proteins, here we also explore whether N-mutHtt and α-syn co-
aggregate within the same filamentous microaggregates or whether they instead form 
independent microaggregates. Finally, to decipher to which extent α-syn might 
contribute to polyQ induced toxicity, we here combine R6/1 N-mutHtt mice with α-syn 
knock-out mice (24) and subject them to behavioral and histopathological analysis. 
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RESULTS 
Huntingtin and -synuclein co-localize in inclusions of HD patients. 
In agreement with a previous report (17), by performing immunohistochemistry with 
anti-α-syn antibodies on postmortem brain tissue from three grade 4 HD patients and 
three control subjects, we observed α-syn-positive inclusions in the striatum of patients 
and extended this finding to the cerebral cortex (Fig. 1A-D). As shown in Figure 1A, 
control subjects show a diffuse nerve terminal pattern while HD subjects also show 
abundant bead-like neuropil inclusions (see solid black arrows in Fig. 1B-C). Less 
frequently, α-syn immunoreactivity could also be detected in larger cytoplasmic 
perinuclear inclusions (see empty arrow in Fig. 1C) and, very rarely, in small 
intranuclear inclusions (see thin black arrow in Fig. 1D). We then performed double 
immunofluorescence to explore whether α-syn-positive inclusions coincide with Htt-
positive inclusions. As shown in Figure 1E-J, α-syn-positive inclusions represent a 
fraction of the N-mutHtt-positive inclusions in neuropil and dystrophic neurites of HD 
brains. More precisely, 21% of the Htt-positive inclusions with diameter > 2.5 µm and 
8% of the Htt-positive inclusions with diameter < 2.5 µm were also positive for α-syn. 
Furthermore, co-localization with α-syn was also observed when the detection of 
inclusions in HD brain was performed with an anti-ubiquitin antibody (data not shown). 
 
-synuclein is detected in inclusion bodies of HD mouse models, but forms 
independent filamentous microaggregates. 
Mouse genetics can be a powerful tool to explore the relevance of α-syn to the 
pathogenesis of polyglutamine disease. Accordingly, we decided to test whether α-syn 
could be detected in inclusions of a commonly used mouse model of HD, namely, the 
R6/1 mouse line. These mice express N-mutHtt with a 116 CAG repeat and they show 
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abundant inclusions in striatal and cortical neurons as well as in other brain regions and 
develop a progressive HD-like behavioral phenotype (22). Immunohistochemistry with 
anti-α-syn antibodies in the brain of R6/1 mice revealed, apart from the widespread 
nerve terminal staining, the presence of some cytoplasmic or neuropil α-syn-positive 
inclusions (Fig. 2A). This is in agreement with a previous study performed on a mouse 
model expressing full length mutant Htt (17). However, α-syn-positive inclusions in the 
brain of R6/1 mice were rare in comparison to those found in human HD brain. By 
performing double immunofluorescence experiments we then confirmed that α-syn-
positive inclusions in the brain of R6/1 mice are a subset of the Htt-positive neuropil 
inclusions (Fig. 2B). Similar results were obtained when the inclusions in R6/1 brains 
were labeled with an anti-ubiquitin antibody (Fig. 2C). 
 
As exemplified in Figure 2D and in Supplementary figure 1, Htt inclusions in human 
(25), and mouse (23, 26) brain tissue are ultrastructurally composed of filamentous 
material. Both N-mutHtt and α-syn are known to aggregate following the classic 
amyloidogenic cascade from soluble oligomers to filamentous microaggregates (8, 27-
30). We have previously reported a method for the isolation of such filamentous 
aggregates from the brain of HD mouse models (23). In view of the co-localization of 
N-mutHtt and α-syn in inclusions of R6/1 mice, we wondered whether N-mutHtt and α-
syn would be co-aggregated in the same filaments. To explore this, we performed 
filament preparations from R6/1 mice and subjected them to double immuno-electron 
microscopy with anti-N-mutHtt and anti-α-syn antibodies. As shown in Figure 2E-F, the 
prominent N-mutHtt-positive filaments obtained from R6/1 mice were not immuno-
decorated with the anti-α-syn antibody. The same result was obtained when the filament 
extraction was performed from brain tissue from a different HD mouse model, namely 
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the inducible HD94 mouse line (Fig. 2G-K). In both R6/1 and HD94 mice, the α-syn 
antibody decorated independent and smaller filaments (Fig. 2F, I-K). To further explore 
this and to verify the specificity of the -syn immunodecoration, we performed filament 
preparations from R6/1 mice and, in parallel, also from wild type and α-syn knock-out 
mice as controls. Interestingly, analysis of the corresponding fractions from wild type 
mice revealed the presence of the same type of anti-α-syn-decorated filaments (Fig. 2L), 
although they were much less abundant than in the R6/1 samples (Fig. 2M; see 
quantification in Fig. 2N). The specificity of the detection of α-syn-decorated filaments 
was evidenced by their absence in samples from α-syn knock-out mice (Fig. 2N). In 
summary, apart from Htt-positive filaments, independent α-syn-positive filaments were 
observed in samples from R6/1 and HD94 mice. These α-syn-positive filaments were 
not exclusive of mice expressing mutant Htt, as they can also be observed in wild type 
mouse samples. However, they are much more abundant in N-mutHtt expressing mice. 
Therefore, since α-syn could not be detected in the Htt filaments obtained from HD 
mouse samples while it was found in different shorter filaments, we conclude that α-syn 
and N-mutHtt form independent filamentous microaggregates in vivo. Thus arguing 
against mixed cross-seeding and suggesting that α-syn and N-mutHtt co-localization in 
certain inclusions probably reflects the coalescence of independent homomeric 
microaggregates into the same inclusion bodies. 
 
α-synuclein knock-out results in decreased number of Htt inclusions in exon1-
HttQ72 transfected neurons and in R6/1 mice. 
Since it was formerly described that α-syn overexpression promoted Htt aggregation in 
cellular models of HD (20, 21), we wondered whether α-syn deficiency would affect in 
the opposite manner the formation of N-mutHtt inclusions in a cell model. For this, we 
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performed striatal primary cultures from wild type (Wt) and α-syn knock-out (α-Syn-/-) 
mice and transfected them with exon 1-Htt with 17 (Q17) or 72 (Q72) CAG repeats 
each coupled to the enhanced green fluorescent protein (EGFP). After 16 h of 
transfection with Q17-EGFP, Wt and α-Syn-/- cells showed an even distribution of 
Q17-EGFP green fluorescence all over the cytoplasm (data not shown). Transfection 
with Q72-EGFP resulted in inclusion formations and yielded differences between Wt 
and α-Syn-/- cells (Fig. 3A). Interestingly, the percentage of transfected cells with 
diffuse fluorescence and no inclusions was significantly higher in Q72-EGFP α-Syn-/- 
cultures than in Q72-EGFP Wt cells (70.77±2.33% vs. 50.19±1.7%; P=0.002), as shown 
in histograms in Figure 3B-C. Inclusion counting was done considering two types of 
inclusions depending on whether they were smaller or bigger than 3.5 m in diameter. 
Interestingly, Q72-EGFP α-Syn-/- cells presented less inclusions of the highest size than 
Q72-EGFP Wt cells (26.09±2.88% vs. 46.32±2.01%; P=0.005). 
 
In view of these results, we decided to explore the effect of the lack of -syn on the load 
of inclusions in vivo in a mouse model of HD. For this, we produced a small group of 
R6/1 mice in -syn knock-out background by breeding with mice with a targeted 
deletion of the α-syn gene (24) and analyzed the number of Htt-positive inclusions at 
symptomatic ages. Sagittal brain sections of 8-month old R6/1 and R6/1;α-Syn-/- mice 
were immunostained with anti-N-terminal-Htt antibody. Htt-positive inclusions were 
abundant in the striatum of R6/1 mice at this age (Fig. 3D) and we quantified the 
number of inclusions with diameter higher than 6 m. In good agreement with the 
results from primary transfected neurons, the number of striatal inclusions was lower in 
R6/1 mice with null α-syn gene dosage (R6/1 vs. R6/1;α-Syn-/-: 2138.80±177.73 
inclusions/mm
2
 vs. 1626.53±100.80 inclusions/mm
2
; P=0.015) (Fig. 3E). However, this 
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decrease in the number of inclusions seems to occur only at late stages of R6/1 mice 
since it was not apparent in mice analyzed at the age of 5 months (data not shown). In 
summary, these results indicate that α-syn deficiency results in diminished number of 
N-mutHtt inclusions, not only in transfected primary neurons, but also in vivo in the 
brain of HD transgenic mice. 
 
We then investigated whether the decrease in the number of inclusions observed in the 
striatum of 8-month old R6/1;α-Syn-/- mice correlated with changes in the proteolytic 
machinery of the cell. For this, we performed western blot analysis of proteins 
indicative of the status of the ubiquitin proteasome system (UPS) or the autophagy in 
the striatum of 8-month old R6/1;α-Syn-/- mice. As shown in Figure 3F, the poly-
ubiquitin smears previously reported to be increased in R6 mice respect to wild type 
mice (31) were not significantly affected by the absence of α-syn. Thus suggesting that 
the decrease in the number of inclusions observed in R6/1;α-Syn-/- mice is not due to a 
different status of the UPS. Regarding autophagy, we measured by Western blot the 
levels of beclin-1 and of Atg5-Atg12 that are proteins involved in early and late stages 
of autophagy, respectively (Fig. 3G). Beclin-1 levels in R6/1 mice were unaffected by 
the knock-out of α-syn. However, the level of the Atg5-Atg12 complex shows a 
tendency to increase in R6/1 mice as the α-syn gene dosage decreases. Thus suggesting 
a facilitation of late stages of autophagy by α-syn knock-out. This might in part explain 
the decrease in the number of inclusions observed in R6/1;α-Syn-/- mice and fits well 
with the previous report of excess α-synuclein acting as a negative regulator of 
autophagy (21). 
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Analysis of the effect of α-synuclein-deficiency on the apoptosis and atrophy 
observed in striatum of R6/1 mice 
We wondered if the decrease in Htt-positive inclusions in R6/1 mice in α-syn knock-out 
background would correlate with changes in other histopathological HD hallmarks, such 
as cell death or striatal atrophy. To test whether reduction in the number of inclusions 
correlates with differences in the rate of striatal apoptotic cell death observed at late 
stages of disease in R6/1 mice, we performed immunohistochemistry for cleaved 
caspase-3. Representative images in Figure 4A show the presence of positive cells for 
cleaved caspase-3 immunostaining in striatum at 8 months of age. As shown in 
histogram in Figure 4A, the number of cleaved caspase-3 cells in R6/1; α-Syn-/- mice 
presented a tendency to be lower than that in R6/1 mice and comparable to that 
observed in wild type mice. Similar results were obtained when the rate of apoptosis 
was analyzed by TUNEL staining (Fig. 4B). We then analyzed striatal volume in 
sagittal sections of transgenic mice by using the Cavalieri method. As seen in the 
histogram in Figure 4C, 8 month old R6/1 mice presented atrophy within the range of 
what has been described before (32), but this was not affected by the gene dosage of α-
syn as it was homogeneous within the R6/1, R6/1;α-Syn+/- and R6/1;α-Syn-/- groups. 
 
α-synuclein deficiency does not affect lifespan but attenuates body weight loss in 
R6/1 mice 
In view of the results concerning inclusion load and incidence of apoptosis obtained in 
the first group of R6/1 mice in -syn knock-out background, we decided to produce a 
bigger experimental group of mice for behavioral studies to explore whether α-syn is a 
relevant player in N-mutHtt-induced disease in vivo. This approach is favored by the 
fact that α-syn gene knock-out mice do not show any obvious behavioral abnormality 
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per se (24). By combining R6/1 mice and α-syn knock-out mice, we therefore obtained 
mice with any of the six following experimental genotypes: wild type mice (Wt), mice 
with an heterozygous deletion of the α-syn locus (α-Syn+/-), mice with an homozygous 
deletion of the α-syn locus (α-Syn-/-), mice that express N-mutHtt with normal α-syn 
alleles (R6/1), mice that express N-mutHtt with an heterozygous deletion of the α-syn 
locus (R6/1;α-Syn+/-) and mice that express N-mutHtt with an homozygous deletion of 
the α-syn locus (R6/1;α-Syn-/-). The breeding protocol starting with R6/1 and α-Syn-/- 
mice is shown in Supplementary figure 2A. Briefly, R6/1 male mice were crossed with 
α-Syn-/- female mice. Then, R6/1;α-Syn+/- and α-Syn+/- mice from the resulting 
offspring were intercrossed to obtain the six mentioned experimental genotypes (Suppl. 
Fig. 2B). This way, a total of 264 mice were generated that showed a normal mendelian 
segregation among the six possible genotypes, as confirmed by chi-square analysis 
(Suppl. Fig. 2C; P=0.414), thus indicating no embryonic lethality associated to any of 
the possible genotypes. 
 
As a global indicator of the potential effect of α-syn gene dosage on polyQ-induced 
disease in vivo, life expectancy was monitored in these mice. Figure 5A shows the 
cumulative survival for the six genotypes calculated by means of the Kaplan-Meier 
analysis. Obviously, as previously reported, significant differences in lifespan were 
observed between non-N-mutHtt-expressing and N-mutHtt-expressing mice (pLog 
Rank≤0.0005, pBreslow≤0.0005, pTarone-Ware≤0.0005). However, there were no significant 
differences among N-mutHtt-expressing mice regarding survival. Lifespan for R6/1 
mice was 297.3710.28 days, for R6/1;α-Syn+/- mice was 289.009.66 days and for 
R6/1;α-Syn-/- mice was 289.3510.26 days. 
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As an additional global indicator of the potential effect of α-syn gene dosage on polyQ-
induced disease in vivo body weight was monitored along the whole study. As 
extensively reported (22, 33-35), R6/1 mice failed to show the progressive weight gain 
that wild type mice experience from 2.5 to 8 months of age. Figure 5B shows body 
weight evolution along time of the six genotypes expressed as percentage respect to Wt 
mice. N-mutHtt-expressing mice presented differences respect to Wt mice since early 
ages in the study. However, these differences did not appear at the same time in the 
three R6/1 groups. Thus, whereas R6/1 and R6/1;α-Syn+/- mice showed a decrease in 
body weight with respect to Wt mice at 2.5 months (Wt vs. R6/1: 100±1.51% vs. 
82.41±2.78%, P=0.019; Wt vs. R6/1;α-Syn+/-: 100±1.51% vs. 90.74±1.54%, P=0.009), 
in the case of R6/1;α-Syn-/- mice the difference was not seen until the age of 4 months 
(Wt vs. R6/1;α-Syn-/-: 100±4.77% vs. 81.64±3.04%, P=0.023). In fact, as shown in 
Figure 5C-D body weight of R6/1;α-Syn-/- mice was almost 20% higher than that of 
R6/1 at 2.5 and 4 months (2.5 months: P=0.004; 4 months: P≤0.0005) and milder but 
significant differences were maintained along the whole study. In summary, α-syn 
knock-out delays body weight deficit in R6/1 from 2.5 to 4 months of age and keeps 
attenuating it up to more advanced stages of disease progression. 
 
α-synuclein deficiency attenuates early motor impairment in R6/1 mice 
We then assessed the potential role of α-syn in mediating the motor phenotype of R6/1 
mice. Scoring of clasping in the tail suspension test is a common assay to evaluate 
involuntary movements in HD mouse models (22, 36). Accordingly, mice were 
recorded for 30 s and the videos were stopped every 2 s to score each mouse and we 
analyzed the cumulative percentage of mice showing clasping. Since no gender 
differences were detected, male and female mice were grouped together for analysis of 
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genotype effect (Fig. 6A). Only N-mut-Htt-expressing mice showed clasping phenotype 
along the whole study starting at the age of 4 months. At this age, 60% of the R6/1 mice 
presented clasping phenotype. In contrast, only 33.3% and 28.5 % of R6/1;α-Syn+/- and 
R6/1;α-Syn-/- mice respectively showed clasping (P≤0.005). However, this beneficial 
effect of α-syn deficiency occurs only at initial stages of disease progression as the three 
R6/1 groups presented a similar percentage of clasping phenotype at 6 and 8 months of 
age.  
 
Other common motor test widely used to examine HD mouse models is rotarod. It has 
been recently described that accelerating rotarod is more sensitive than fixed-speed 
rotarod for detecting early motor deficits in R6 mice (37). Thus, mice were analyzed on 
the rotarod apparatus set to accelerate from 4 to 40 rpm along a 5 min period and mice 
were tested in four trials with 1 h inter-trial periods. Mice were examined at the age of 
2.5, 4, 6 and 8 months. Since no gender differences were detected, male and female 
mice were grouped together for analysis of genotype effect. As expected, N-mutHtt-
expressing mice showed a deficit in this motor coordination task (Fig. 6B). This deficit 
started at the age of 4 months and then showed a progressive worsening until the last 
time point of the study, at 8 months. Interestingly, analysis of the percentage of mice on 
rod at the highest speeds of the accelerating paradigm (Fig. 6C) revealed that R6/1;α-
Syn+/- and R6/1;α-Syn-/- mice perform better than R6/1 mice at 4 and 6 months of age 
(4 months, 36 rpm: P=0.048; 4 months, 40 rpm: P=0.005; 6 months, 32 rpm:  P=0.003; 
6 months, 36 and 40 rpm: P=0.001). In conclusion, analysis of clasping phenotype and 
rotarod performance revealed that α-syn deficiency attenuates motor phenotype of R6/1 
mice at early stages of disease progression. 
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DISCUSSION  
 
Increased levels or aggregation of α-syn are sufficient to induce neurodegeneration as 
evidenced by the facts that duplication or triplication of the α-syn gene or point 
mutations that confer a higher propensity for α-syn self-aggregation leads to severe 
forms of PD (13, 14, 16). Here we have confirmed in HD postmortem brains and in the 
R6/1 mouse model of HD the accumulation of α-syn in polyQ-inclusions that had been 
previously reported in patients of HD and other CAG repeat disorders (17-19). 
Furthermore, based on a method that we previously established to isolate filamentous 
microaggregates like those that form inclusion bodies (23), we here demonstrate that N-
mutHtt and α-syn form independent homomeric filaments and that N-mutHtt expression 
increases the load of α-syn filamentous microaggregates. Thus, arguing against mixed 
cross-seeding and rather fitting with the suggested N-mutHtt-induced progressive 
disruption of cellular protein folding (5, 38), leading to homomeric aggregation of 
misfolding-prone proteins and subsequent coalescence of independent homomeric 
microaggregates into the same inclusion bodies. Finally, to explore whether α-syn is a 
modifier of polyQ-induced toxicity in vivo we took advantage of mouse genetics and 
found that α-syn knock-out results in diminished number of N-mutHtt inclusions in 
transfected mouse neurons and also in vivo in the brain of HD transgenic mice. Most 
importantly, α-syn knock-out also results in attenuation of the body weight-loss and of 
the early motor phenotype of HD mice. 
 
Since α-syn knock-out per se does not induce a clear neurological phenotype in mice 
(24), combination of an HD mouse model and α-syn knock-out mice represents a 
powerful approach to decipher whether polyQ-induced alterations in α-syn proteostasis 
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might contribute to HD pathogenesis. The fact that α-syn deficiency attenuates body 
weight loss and early motor dysfunction of R6/1 mice strongly indicates that α-syn acts 
as an additional mediator of toxicity in early stages of polyQ-induced disease in vivo. 
The also reported effect of α-syn deficiency on the load of inclusion bodies suggests 
that competition for the protein folding machinery and/or interfering with protein 
degrading systems such as autophagy and the ubiquitin-proteasome system (UPS) might 
account for the recruitment of α-syn as an additional mediator of polyQ toxicity. 
Collectively, out data demonstrate that α-syn is a modifier of polyQ-induced toxicity in 
vivo and we will discuss below the possible underlying mechanisms. 
 
Regarding the possible competition for the protein folding machinery, it has been shown 
that expression of expanded polyQ in various C. elegans strains expressing temperature 
sensitive mutants of structurally and functionally unrelated proteins results, at 
permissive temperatures, in induction of the phenotype associated with the aberrant 
conformation (5). Thus, suggesting that polyQ expression induces a progressive 
disruption of the folding capacity of the cell. Since there are many marginally stable or 
folding-defective proteins in the cell that may be affected by such disruption in the 
folding machinery, this has been postulated as a feedback mechanism that might explain 
the similarities among the many conformational neurodegenerative diseases (5). Our 
study suggests that α-syn may be one of such folding-defective proteins affected by N-
mutHtt expression in vivo. N-mutHtt-induced alterations in α-syn conformation and 
aggregation could then significantly contribute to disease progression in the early stages 
but, as additional conformationally unstable proteins are engaged, the contribution of α-
syn might become marginal thus explaining why α-syn knock-out does not significantly 
influence lifespan and late motor phenotype of R6/1 mice.  
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Regarding protein degradation, α-syn has been reported to be degraded mainly through 
autophagy (39). However, it has also been reported that proteasome inhibitor 
administration to cell models of polyQ disease results in increased formation of 
inclusion bodies and that these are immuno-positive for α-syn (40) and it is well 
documented that UPS and autophagy alterations affect each other, probably as 
compensatory mechanisms (41).  
 
Whether the UPS is impaired in polyQ disease has been a matter of debate. On one 
hand, impaired proteasome activity was reported in polyQ cell models (42, 43) and we 
have also shown that filamentous microaggregates of N-mutHtt are able to impair 26S 
proteasome activity in vitro (44). On the contrary, proteasome activity was not 
diminished in brain homogenates of HD mice (45) and no global impairment of the UPS 
is detected under steady state expression of N-mutHtt in adult HD mice (31, 46, 47) 
despite accumulation of high molecular weight poly-ubiquitin conjugates (31). 
However, UPS impairment has been confirmed in vivo in mouse models but only 
locally at the synapse (48) or transiently upon acute N-mutHtt expression before 
inclusion formation takes place (47). In fact, such transient nature of polyQ-induced 
UPS impairment might also explain the transient beneficial effect of α-syn knock-out in 
early disease progression of R6/1 mice. α-Syn mediated toxicity might occur only 
transiently due to a recovery of the UPS upon efficient inclusion body formation. 
Regarding  possible differences in the status of the UPS to account for the decrease in 
the number of inclusions observed in the striatum of 8-month old R6/1;α-Syn-/- mice, 
the here reported data of poly-ubiquitin smears not being significantly affected by the 
absence of α-syn argues against this possibility. 
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Regarding autophagy, here we show that the level of the Atg5-Atg12 complex shows a 
tendency to increase in R6/1 mice as the α-syn gene dosage decreases. This suggests a 
possible increase in autophagy that might in part explain the decrease in the number of 
inclusions observed in 8-month old R6/1;αSyn-/- mice and fits with the recent reports of 
α-syn as a negative regulator of autophagy. On one hand, excess α-syn has been shown 
to impair macroautophagy via Rab1a inhibition (21). Consequently, excess α-syn results 
in increased load of aggregates in cell models expressing exon-1 Q74 Htt and in 
increased neurodegeneration in flies expressing exon-1 Q120 Htt in eyes (21). More 
recently, a positive feedback loop model of excess α-syn inducing lysosomal 
dysfunction has been proposed (49). More precisely, in the context of the clinical link 
between the lysosomal storage disorder Gaucher disease (GD) and PD, Mazulli et al. 
reported that GD-linked mutations in glucocerebrosidase (GCase) result in increased 
level of glucosylceramide that facilitate formation of α-syn oligomers. This, in turn, 
hampers vesicle transport between endoplasmic reticulum and the Golgi apparatus, the 
main trafficking route for GCase to reach the lysosome. Therefore, it is possible that N-
mutHtt-induced alterations in α-syn conformation and aggregation might contribute to 
in vivo progression of HD in part by affecting lysosomal function and autophagy. 
 
We are not the first to describe α-syn accumulation in neurodegenerative diseases other 
than the typical synucleinopathies such as PD or Lewy body disease. As already 
mentioned, this had been described for various PolyQ diseases (17-19) and, 
interestingly, also for Alzheimer´s disease (AD). Since AD patients also show the 
typical tau and Aβ depositions, this disease has been considered a “triple brain 
amyloidosis” (50) and there are many in vivo studies supporting that α-syn affects Aβ 
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and tau pathology. As examples of α-syn and tau interaction, a patient with the α-
synA53T mutation, exhibited neurofibrillar tangle pathology in addition to Lewy bodies 
(51) and a small percentage of the M83 α-synA53T transgenic mouse line also exhibits 
tau inclusions (52). As an example of α-syn and A interactions, double transgenic α-
syn/amyloid precursor protein (APP) mice exhibit increased α-syn deposition versus 
single-transgenic mice (53). 
 
It had also been hypothesized that Aβ, tau, and α-syn promote the aggregation of one 
another probably through a cross-seeding mechanism (52). In fact, in vitro aggregation 
studies revealed that co-incubation of α-syn and tau promotes their polymerization (52). 
However, in good agreement with our results showing isolation of independent α-syn 
and N-mutHtt filaments from brain of R6/1 mice, analysis of filaments formed in vitro 
by co-incubation of tau and α-syn also revealed that they were essentially independent 
homopolymers (52). Heteromeric cross-seeding appears to occur only among proteins 
with equivalent molecular structures due to sequence similarity. Accordingly, N-mutHtt 
has been reported to cross-seed and form mixed fibrillation only with Q/N rich proteins 
such as the RNA-binding protein TIA-1(54) and the NM domains of Sup35p (55). Since 
α-syn does not share such a sequence similarity with tau or with N-mutHtt, it is not 
surprising that Giasson and co-workers and we observed independent homomeric 
filaments. Therefore, the coincidence of N-mutHtt and α-syn in inclusions is most likely 
the consequence of coalescence of the specific filaments in bigger aggregates similar to 
what has been described in cellular models expressing polyQ fusion proteins (38). 
 
In summary, here we have confirmed in postmortem HD brains and in the R6/1 mouse 
model the accumulation of α-syn in polyQ inclusions that was previously reported in 
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brains of patients of various CAG repeat disorders. Furthermore, we found that N-
mutHtt and α-syn form independent homomeric filaments. Finally to elucidate if α-syn 
is recruited as an additional player in pathogenicity triggered by N-mutHtt, we brought 
R6/1 mice to α-syn deficient backgrounds. Since α-syn deficiency results in 
improvement of body weight and of motor tasks in early symptomatic mice, we 
conclude that α-syn is a modifier of polyQ toxicity in vivo. The observed effect on α-syn 
knock-out on N-mut-Htt inclusion formation suggests that competition for protein 
folding and degradation machineries may underlie the observed beneficial effects of α-
syn knock-out. Finally, our study also raises the possibility that any PD-related new 
experimental approach aimed to counteract α-syn toxicity might also be used to slow 
HD progression. 
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 MATERIALS AND METHODS 
 
Human samples 
Brain specimens used in this study were removed at autopsy from three HD and three 
age-matched controls following the protocols of nervous tissue donation approved by 
the local Ethical Committees of the Barcelona and Bellvitge brain banks. The post-
mortem delay in tissue processing was between 4 and 15 h in both groups. The 
neuropathological examination in HD cases revealed a diagnosis of HD grade 4 
following the criteria of Vonsattel (56), revised in (57). 
 
Animals 
R6/1 mice transgenic for the human exon 1 huntingtin gene, in the B6CBAF1/J 
background (22) were used. Special attention was paid in order not to use B6CBAF1 
mice from Harlan at any production step, since C57B6 mice from Harlan are known to 
be natural mutants lacking α-syn (58). α-Syn knock-out (α-Syn-/-) mice (B6; 129X1-
Snca
tm1Rosl
/J;(24)) were purchased from Jackson Laboratories. To obtain R6/1 mice in 
α-syn+/- and α-syn-/- backgrounds, male R6/1 mice (R6/1) were crossed with α-Syn-/- 
females. From the offspring, a second cross was set with R6/1;α-Syn +/- male mice and 
α-Syn +/- females, to achieve six different genotypes which covered from null to two α-
syn gene doses and the presence or absence of the R6/1 transgene (Supplementary 
Figure 2).  
Mice were bred at Centro de Biología Molecular “Severo Ochoa” (Madrid, Spain). Four 
or five mice were housed per cage with food and water ad libitum. Mice were 
maintained in a temperature-controlled environment on a 12 h light/dark cycle with 
lights onset at 7:30 A.M. All experiments were performed in accordance with 
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institutional guidelines approved by the ethical committee of Consejo Superior de 
Investigaciones Científicas (CSIC). 
 
Immunohistochemistry and immunofluorescence in human tissue 
Immunohistochemistry: human cryoprotected sections, 30 µm thick, were pre-treated in 
boiling epitope unmasking solution (SSC, 150 mM NaCl and 15 mM sodium citrate, pH 
7.0) for 8 min to unmask aggregated α-syn. After cooling the slices in distilled water, 
sections were washed twice in PBS and endogenous peroxidase activity was inactivated 
with H2O2 in methanol for 30 min at room temperature and then sections were incubated 
in blocking solution (1% BSA, 0.5% fetal bovine serum and 0.2% Triton X-100 in PBS) 
for 1 hour at room temperature . Then, sections were incubated with mouse anti-α-Syn 
primary antibody (Novocastra) overnight at 4ºC. After washing with PBS, sections were 
incubated with the secondary components of the Elite Vectastain kit (Vector 
Laboratories). Diaminobenzidine (Sigma) was used as peroxidase substrate and, once 
dried, sections were cover slipped with PermaFluor Aqueous Monting Medium 
(Thermo Scientific). 
Immunofluorescence: human paraffin sections, 4 µm thick, were pre-treated with 5% 
formic acid for 3 min to unmask aggregated α-syn and then incubated in 10% fetal 
bovine serum diluted in PBS to avoid non-specific binding. Sections were incubated 
overnight at 4°C with a combination of two primary antibodies: anti-α-synuclein (aa 
111-131, Chemicon) and anti-N-terminal Htt (MAB5374, Millipore) or anti-α-synuclein 
(C-20)-R (Santa Cruz Biotechnology) and anti-N-terminal Htt (MAB5374). After 
washing with PBS, the sections were incubated with secondary antibodies: anti-rabbit 
Alexa 546 and anti-mouse Alexa 488 (Molecular Probes, Carlsbad, CA, USA) or anti-
rabbit Texas Red-X 587 and anti-mouse Oregon Green 488 (Invitrogen). Nuclei were 
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counterstained with DAPI (Calbiochem). Subsequently, the sections were mounted with 
Fluorescent Mounting Medium (Dako), sealed and dried overnight at 4°C. Sections 
were examined with a Leica TCS-SL confocal microscope. For inclusion counting, 20 
fields were counted at 40x magnification in an Axioskop 2 plus upright microscope 
(Zeiss) connected to a Coolsnap FX color camera (Roper Scientific). Data were 
expressed as percentage of Htt inclusions positive for α-synuclein labeling. 
 
Immunohistochemistry and immunofluorescence in mouse tissue 
In each experiment, all mice were processed in parallel and samples have been treated 
identically. Briefly, mice were sacrificed by CO2, and brains were removed and halved 
sagittally immediately after decapitation. Left hemispheres were processed for 
histology, fixed with 4% paraformaldehyde (PFA) in Sorensen´s phosphate buffer 
overnight at 4°C, and then were immersed in 30% sucrose in PBS for 48 h for 
cryoprotection. Next, samples were frozen in OCT (Optimal Cutting Temperature, 
Tissue-Tek) and stored at -80ºC until use. Sagittal sections (30 µm) were cut on a CM 
1950 Ag Protect freezing microtome (Leica), and placed and stored in a solution 
containing 30% glycerol and 30% ethyleneglycol in 0.02 M monobasic phosphate 
buffer at pH 7.2 at -20 ºC. To detect α-syn aggregates by immunohistochemistry or by 
immunofluorescence, a previous epitope unmasking step was performed as above 
described for the human tissue staining. 
Immunohistochemistry: For -syn detection in mouse tissue sagittal sections were pre-
treated by boiling in epitope unmasking solution (SSC) for 8 min. After cooling the 
slices in distilled water, sections were pretreated for 30 min in 1% H2O2/PBS, followed 
by 1 h in blocking solution and incubated overnight with primary antibodies: mouse 
anti-α-Syn-1 (BD Transduction Laboratories), mouse anti-N-terminal Htt (MAB5374, 
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Millipore) and rabbit anti-cleaved caspase-3 (Asp175) (Cell Signaling). Finally, the 
peroxidase activity was developed with the Elite Vectastain kit (Vector Laboratories) 
using diaminobenzidine (Sigma). Sections were cover slipped with PermaFluor 
Aqueous Monting Medium (Thermo Scientific). Digital images were capture with an 
Olympus Bx 51 microscope coupled to a Color View IIIu digital camera with 20x 
objective lens with the help of the Olympus Soft Imaging System. 
Immunofluroscence: after the unmasking step in SSC, sagittal sections were incubated 
with 1% Triton X-100 in PBS and followed by blocking solution (1% BSA and 0.1% 
Triton X-100 in PBS). Sections were further incubated with two combinations of 
primary antibodies: mouse anti-N-terminal Htt (MAB5374, Millipore) and rabbit anti-α-
Syn (C-20)-R (Santa Cruz Biotechnology) or with rabbit anti-ubiquitin (Dako) and 
mouse anti-α-Syn [4D6] (Abcam) at 4ºC overnight. As secondary antibodies, anti-
mouse Oregon Green 488 and anti-rabbit Texas Red-X 587 or anti-rabbit Oregon Green 
488 and anti-mouse Texas Red-X 587 (Invitrogen) were used. Nuclei were stained with 
DAPI (Calbiochem). Once air dried in darkness, sections were cover slipped with 
PermaFluor Aqueous Monting Medium (Thermo Scientific). Images were acquired with 
the vertical Axio Imager.M2 microscope using the LSM510 software (Carl Zeiss) with a 
100x, 1.4 numerical aperture oil immersion objective or with the vertical Axioskop2 
plus microscope using the Metavue 5.07 software (Universal Imaging) with a 63x, 1.4 
numerical aperture oil immersion objective. 
 
Huntingtin inclusions counting in mouse samples 
Four spaced regularly sections of each mouse were immunostained for anti-N-terminal 
Htt (MAB 5374, Millipore). Digital images of striatal Htt inclusions were captured with 
an Olympus Bx 51 microscope, Color View IIIu digital camera with a 40x objective 
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lens with the help of the Olympus Soft Imaging System. The number and size of 
inclusions were determined using the ImageJ software with the Analyze Particles 
routine (size 2.89-14.45 m2, threshold 0-75, circularity 0.81-1.00). Data are 
represented as the mean  SEM.  
 
TUNEL assay 
For each mouse, five regularly spaced sagittal sections spanning the whole striatum 
were processed according to the In Situ Cell Death Detection Kit protocol (POD, 
Roche). All analyses were performed in a blinded manner, and results were presented as 
the number of TUNEL-positive cells per 30-μm section.  
 
Striatal volume analysis 
Striatal volume was determined in every sixth sagittal section by using the Cavalieri 
method. Digital images were captured at a 2.5x magnification (Canon EOS 450D digital 
camera). Striatal area from 15 sections for each animal was calculated by means of the 
ImageJ software. Considering a separation of 180 m between each section, total 
striatal volume of each mouse was calculated. Data are represented as the mean  SEM.  
 
Western blot 
Mouse brains were quickly dissected on an ice-cold plate. Extracts for western blot 
analysis were prepared by homogenizing the striatum in ice-cold extraction buffer 
consisting of 20 mM HEPES pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 
mM sodium orthovanadate, 5 mM EDTA, and protease inhibitors (2 mM PMSF, 10 
µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml pepstatin). The samples were 
centrifuged at 15,000 x g for 20 min at 4°C. The resulting supernatant was collected and 
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protein content was determined by Bradford. Five micrograms of total protein were 
electrophoresed on 10% SDS-polyacrylamide gel and transferred to a nitrocellulose 
membrane. The following primary antibodies were used: anti-ubiquitin (clone FK2, 
Millipore), anti-beclin1 (Santa Cruz Biotechnology), anti-Atg5 (Millipore) and anti--
actin (Sigma). The blots were incubated with the primary antibody at 4°C overnight in 
5% non-fat dried milk followed by secondary polyclonal anti-mouse or anti-rabbit 
immunoglobulins conjugated with HRP (DAKO Cytomation) and ECL detection  
(Perkin Elmer).  
 
Tissue processing for electron microscopy 
For electron microscopy, immunostained vibratome sections were processed as 
previously described (59). Briefly, the sections were postfixed in 2% OsO4 for 1 h, 
dehydrated, embedded in Araldite, and flat-mounted in Formvar-coated slides, using 
plastic coverslips. After polymerization, selected areas were photographed, trimmed, 
reembedded in Araldite, and resectioned at 1 m. These semithin sections were 
rephotographed and resectioned in ultrathin sections. The ultrathin sections were 
observed in a Jeol electron microscope, without heavy metal staining to avoid artifactual 
precipitates. 
 
Immunoelectron microscopy of purified filamentous microaggregates 
Isolation of filamentous microaggregates from mouse brain tissue was performed as 
previously described (23). Briefly, forebrains were homogenized in buffer 1 (10 mM 
Tris, 1 mM EGTA, 0.8 M NaCl, 10% sucrose, 0.1% Triton X-100, and protease 
inhibitors) in a glass homogenizer. After centrifugation at 5,000 rpm (Sorvall SS34 
rotor, Thermo Scientific) for 20 min, the supernatant S1 was saved, and pellet P1 was 
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homogenized in buffer 1 and centrifuged again. The supernatants S1 and S2 were 
combined, adjusted to 1% (w/v) N-lauroylsarcosine and 1% (v/v) β-mercaptoethanol, 
and incubated for 2 h at room temperature. After centrifugation at 50,000 rpm (TLA- 
100.3 rotor, Beckman Coulter) for 45 min, filament containing pellets were 
homogenized in buffer 2 (10 mM Tris, 1 mM EGTA, 0.8 M NaCl, 10% sucrose, and 
protease inhibitors), layered over a discontinuous sucrose gradient consisting of 50% 
sucrose and 20% sucrose in buffer 3 (10 mM Tris, 1mM EGTA, 0.8 M NaCl) and 
centrifuged for 2 h at 35,000 rpm (SW40 rotor, Beckman Coulter). The filament 
containing fraction was collected from the 20–50% interface and stored at -70°C until 
use. 
Double immunoelectron microscopy was performed after adsorption of the filament 
containing fraction to electron microscopy carbon-coated grids. Samples were incubated 
with anti-N-terminal Htt MAB5374 (MAB5374, Millipore), anti-N-terminal Htt 
CAG53b (amino acids 1–118 with a 51 polyQ stretch, a kind gift from Dr. Wanker, 
Berlin, Germany) and anti-α-synuclein (C-20) (Santa Cruz Biotechnologies). Grids were 
then incubated with secondary gold-conjugated antibodies (Sigma). Finally, the samples 
were stained with 2% uranyl acetate. Transmission electron microscopy was performed 
in a Jeol (Peabody, MA) model 1200EX electron microscope operated at 100 kV. For 
-syn filament counting, 7 grids for each condition were analyzed by counting 4 fields 
per grid at 25000 x magnification.  
 
Primary neuron culture, transfection, immunofluorescence and inclusion counting 
Primary neuronal cultures were prepared according to modifications of established 
procedures (60). Briefly, Wt or α-Syn knock-out pups were sacrificed at postnatal day 0. 
Striatal tissue was dissected and dissociated with the Papain Dissociation System 
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(Worthington). Striatal neurons were maintained in Neurobasal medium (Invitrogen) 
supplemented with 1% sodium pyruvate, 0.5 mM glutamine, 10% v/v horse serum, and 
1% penicillin/streptomycin, and grown on 3 μg/ml laminin (Sigma) and 10 μg/ml poly-
L-lysine coated  chamber slides (-Slide for high quality microscopy, Ibidi). After 2 h 
of incubation, the culture medium was replaced with Neurobasal medium supplemented 
with 1% sodium pyruvate, 0.5 mM glutamine and 2% B27. Cells were maintained in 
95% air/5% CO2 in a humidified incubator at 37°C.  
Transfection was performed 1 day after plating. Htt constructs comprised  pEGFP-1 
with the N-terminal fragment of Htt with 17 or 72 CAG repeats fused to the enhanced 
green fluorescence protein (EGFP) (kindly provided by Drs. Finkbeiner and Arrasate). 
Cells were transiently transfected with 1μg plasmid DNA and 3 μl Lipofectamine 
(Invitrogen) in 100 μl Neurobasal medium. The mixture was carefully (drop by drop) 
directly added to the medium (without antibiotics) and incubated for 2 h in 95% air/5% 
CO2 in a humidified incubator at 37°C. Next, cells were washed three times with PBS 
and added to Neurobasal medium supplemented with 1% sodium pyruvate, 0.5mM 
glutamine, 2% B27, and 1% penicillin/streptomycin. Transfection efficiency was 
controlled by counting the number of transfected neurons corrected by the total number 
of neurons (a minimum of 300 cells were analyzed per experimental condition). 
Transfection efficiency was between 3% and 6% across all experiments. 
After 16 h of transfection, cells were fixed with 2% PFA in Sorensen´s phosphate buffer 
for 10 min and washed twice with PBS prior fixation in 4% PFA for 10 min. Then, 
slices were washed again in PBS and nuclei were stained with DAPI (Calbiochem). 
Once air dried in darkness, sections were cover slipped with Fluorosave (Calbiochem). 
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For inclusion counting, 60 fields from a total of 8 slices for each condition were counted 
at a magnification of 63x in Axioskop 2 plus upright microscope (Zeiss) coupled to a 
Coolsnap FX color camera (Roper Scientific).  
 
Behavioral tests 
Survival. 134 mice were kept for survival. Life expectancy study was finished at day 
700, 350 days after the last N-mutHtt expressing mouse died spontaneously. Results are 
represented as Kaplan-Meier curves.  
Body Weight. Starting at 2.5 months, mice were weighed once a month. Results are 
represented as the mean  SEM.  
Behavioral testing started at 2.5 months and finished at 8 months, when transgenic mice 
presented several difficulties to perform the tasks. The number of mice used in this 
round of behavioral test was 91.  
Clasping. Mice were suspended by the tail ~ 20 cm above the cage for 30 s and 
recorded. Every 2 s, the video was stopped and the number of limbs clasping was 
observed. For cumulative percentage of mice clasping, the first time the animal clasped 
was scored as positive and was not considered again. Results are represented as the 
cumulative percentage of mice with clasping phenotype. 
Rota-rod. Motor coordination was tested on an accelerating rotarod
 
apparatus (Ugo 
Basile). Initially, each mouse
 
was trained for two days. In the first day, mice performed 
4 trials (1 h intervals) at a fixed speed (4 rpm) for 60 s. In the second day, mice 
performed also 4 trials at a fixed speed at 8 rpm for 60 s. The third day, rotarod
 
was set 
to accelerate from 4 to 40 rpm over 5 min and mice were tested four times (1 h 
intervals). During accelerating trials, the latency of each mouse to fall from the rotarod 
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was measured. Results are represented as the mean  SEM of the latencies to fall in the 
four trials and as the percentage of mice on rod at the highest speeds.  
 
Statistical Analysis 
The normality of the data was tested by means of Shapiro-Wilk test. In view of the 
results, for non-parametric data, the following tests were applied for comparison of 
differences in several variables among genotypes: Mann-Whitney U test to compare -
syn filaments counting; Kruskal-Wallis H test followed by Mann-Whitney U test were 
used in the case of cleaved-caspase-3, TUNEL, striatal volume, body weight and mean 
latency on rod studies. For parametric data, differences in several variables among 
genotypes were analyzed by the following tests: independent two-sample Student´s t 
test was applied for inclusion counting in cell cultures and one-way ANOVA followed 
by Bonferroni post hoc test were used for striatal inclusion counting in R6/1 mice. 
Genotype frequencies, percentage of clasping mice and percentage of mice on rotarod 
were analyzed by means of chi-square test. Cumulative survival was analyzed by 
Logrank, Breslow and Tarone-Ware tests. A critical value for significance of P<0.05 
was use throughout the study. The SPSS 17.0 software was used for statistical analysis. 
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LEGENDS TO FIGURES 
 
Figure 1: Huntingtin and -synuclein co-localize in inclusions of HD postmortem 
human brain. -synuclein immunohistochemistry in samples of human cerebral cortex 
of control subjects (A). or grade 4 HD patients (B-D). In the HD samples, α-synuclein 
immunoreactivity often appears as small inclusions in the neuropil (B-C, solid black 
arrows). It can also occasionally appear as large cytoplasmic perinuclear inclusions 
(empty arrow in C) and, exceptionally, as small intranuclear inclusions (thin black 
arrow in D). Double immunofluorescence staining of cortical sections from HD 
patients. Note that some N-mutHtt-positive cytoplasmic inclusions and dystrophic 
neurites (E, H; green fluorescence) were also labeled with -syn antibody (F, I; red 
fluorescence), as shown in the merged image with DAPI nuclear counterstaining in blue 
(G, J). 
 
Figure 2: -synuclein is detected in Htt inclusion bodies of HD mouse models, but 
forms independent filamentous microaggregates. A, -syn immunohistochemistry in 
cortex of R6/1 mice revealed the presence of bead-like neuropil inclusions (solid black 
arrow) similar to those seen in the human samples. B, Sections from R6/1 mice 
subjected to double Htt (green) and -syn (red) immunofluorescence followed by DAPI 
blue nuclear counterstaining were analyzed under confocal microscope and revealed the 
presence of α-syn in a subset of N-mutHtt-positive cytoplasmic inclusions (white 
arrows). C, Double -syn (red) and ubiquitin (green) immunofluorescence experiments 
were analyzed under a confocal microscope and revealed the presence of -syn in a 
subset of neuropil ubiquitin-positive inclusion bodies (white arrow). D, Ultrastructural 
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transmission electron analysis of an N-mutHtt-stained neuropil inclusion in the striatum 
of an R6/1 mouse. White arrows indicate the filamentous ultrastructure of the aggregate. 
E-M, Immunoelectron microscopy analysis of filamentous aggregates isolated from the 
forebrain of HD mice. E-F, N-mutHtt-positive filaments from R6/1 mice (decorated 
with 5-nm gold particles, black arrows) were not co-decorated for -syn (detected with 
10 nm gold particles). G-K, Filamentous aggregates isolated from the forebrain of 
Tet/HD94 mice. As for R6/1 mice, N-mutHtt filaments (in this case decorated with 10-
nm gold particles, black arrows) were not co-decorated for -syn (detected with 5 nm 
gold particles). In both models, independent -syn filaments were detected (F, I, J and 
K; empty arrows). Fractions from wild type mice showed the same type of anti-α-syn-
decorated filaments (L), although R6/1 samples presented a higher number of anti--
syn-decorated filaments (M) as seen in  histogram in N, that represents α-syn filament 
counting in α-Syn-/-, Wt and R6/1 mice. Data are presented as mean  SEM; *, P < 
0.05. At least four animals per genotype were used.  
 
Figure 3: α-synuclein knock-out results in decreased number of Htt inclusions in 
exon1-HttQ72 transfected neurons and in R6/1 mice. A-C, Primary striatal neuron 
cultures from Wt and -Syn-/- mice were transfected with exon1-Htt-Q72-EGFP (Q72-
GFP) which resulted in inclusion formation (A, white arrows). B, The 100% stacked 
column histogram shows the contribution of cells with inclusions to the total of the 
transfected cells in each genotype. C, Inclusion counting showed that, in Q72-GFP-
transfected -Syn-/- cells, the percentage of cells with inclusions higher than 3.5 m 
was significantly lower than in the Wt cultures. A total of eight independent cultures 
were analyzed. D-E, N-mutHtt immunohistochemistry on brain sections from 8 month-
old R6/1 mice with different -syn dosage. D, Panels show representative images of the 
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striatum. E, Counting of aggregates with diameter higher than 6 m. As in primary 
striatal neuronal cultures, the number of inclusions is lower in -Syn-/- background. F, 
Western blot analysis of poly-ubiquitin smears. Histogram shows no significant 
differences among the three R6/1 genotypes with varying -syn gene dosage. G, 
Western blot analysis of Beclin-1 and of the Atg5-Atg12 complex. Histogram shows no 
differences among the three R6/1 genotypes with varying -syn gene dosage in Beclin-
1 levels, while Atg5-Atg12 complex shows a tendency to increase in R6/1;-Syn-/- 
mice respect to the other R6/1 mice. At least four animals per genotype were analyzed. 
Data are presented as mean  SEM. *, P < 0.05; **, P < 0.01. 
 
Figure 4: Analysis of the effect of -synuclein-deficiency on the apoptosis and 
atrophy observed in striatum of R6/1 mice. A, Immunohistochemistry for cleaved 
caspase-3 on brain sections from 8 month old R6/1 mice with different -syn gene 
dosage. Left panels show representative images of caspase-3 positive cells in the 
striatum (black arrows). R6/1;-Syn-/- mice presented a tendency to fewer cells positive 
for caspase-3 (see histogram on the right), although it did not reach significance. B, 
TUNEL staining in R6/1 mice with different -syn gene dosage. Left panels show 
representative image of TUNEL positive cells in the striatum (black arrows). As in the 
caspase-3 analysis, R6/1;-Syn-/- mice presented a tendency to fewer TUNEL positive 
cells (see histogram on the right). C, Striatal Volume. Representative images of thionine 
stained sagittal sections of Wt and R6/1 mice at 8 months of age (striatal atrophy is 
observed in R6/1 sections). Histogram shows quantification of striatal volume. No 
differences were observed among R6/1 mice with different -syn gene dosage. Results 
are expressed as mean ± SEM. At least three animals per genotype were analyzed.  
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Figure 5: α-synuclein deficiency does not affect lifespan, but attenuates body 
weight loss in R6/1 mice. A, Kaplan-Meier curve for cumulative survival. Lifespan is 
shown over a period of 700 days. Number of mice analyzed: Wt (12), -Syn+/- (38), -
Syn-/- (23), R6/1 (19), R6/1;-Syn+/- (43) and R6/1;-Syn-/- (19). B-D, Body Weight. 
B, Histogram shows the percentage of body weight respect to Wt mice. a: Wt vs. R6/1: 
from 2.5 months onwards; b: Wt vs. R6/1;-Syn+/-: from 2.5 months onwards; c: Wt vs. 
R6/1;-Syn-/-: from 4 months onwards; d: -Syn+/- vs. R6/1;-Syn+/-: from 2.5 
months onwards; e: -Syn-/- vs. R6/1-Syn-/-: from 5 months onwards; f: R6/1 vs. 
R6/1;-Syn+/-: from 2.5 months onwards. C, Body weight of N-mutHtt expressing 
mice with different -syn gene dosage at 2.5 and 4 months of age. D, Data from N-
mutHtt expressing mice with varying gene dosage of -syn were normalized respect to 
their non-N-mutHtt-transgenic counterparts (dashed line). Differences are seen later in 
the case of R6/1;-Syn-/- mice, namely at 5 months of age (#: differences between non-
N-mutHtt expressing mice vs. N-mutHtt expressing mice from this point onwards). 
Furthermore, R6/1;-Syn-/- mice presented higher body weight compared to R6/1 mice 
at all ages (asterisks). Results are expressed as mean ± SEM; # P < 0.05, * P < 0.05, ** 
P < 0.01, *** P < 0.001. Number of mice analyzed: Wt (7), -Syn+/- (18), -Syn-/- 
(20), R6/1 (10), R6/1;-Syn+/- (21) and R6/1;-Syn-/- (14). C and D show only data 
from males while B shows both males and females.  
 
Figure 6: α-synuclein deficiency attenuates early motor impairment in R6/1 mice. 
A, Cumulative percentage of mice showing clasping. The percentage of clasping mice is 
higher in R6/1 than in R6/1;-Syn+/- and R6/1;-Syn-/- groups at 4 months of age. 
After 6 months all N-mutHtt expressing mice presented a similar clasping phenotype. 
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Number of mice analyzed: R6/1 (10), R6/1;-Syn+/- (19) and R6/1;-Syn-/- (12).  B-C, 
Rotarod. B, Evolution from 2.5 to 8 months of age of the mean latency to fall from rod. 
N-mutHtt expressing mice showed a deficit in motor performance from 4 month 
onwards in comparison to the non-N-mutHtt expressing mice (a). C, Percentage of N-
mutHtt expressing mice remaining on rod at the highest speeds. At 4 and 6 months, the 
percentage of R6/1;α-Syn-/- animals able to reach the highest speeds (32, 36 and 40 
rpm) is higher than in R6/1 mice. Number of mice analyzed: Wt (7), -Syn+/- (18), -
Syn-/- (20), R6/1 (10), R6/1;-Syn+/- (21) and R6/1;-Syn-/- (14).  Data are expressed 
as percentage over the total genotype population; *, P < 0.05; **, P < 0.01; ***, P < 
0.001. 
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ABBREVIATIONS 
 
AD: Alzheimer´s disease 
HD: Huntington´s disease 
Htt: Huntingtin 
N-mutHtt: N-terminal-mutant huntingtin 
PD: Parkinson´s disease 
PolyQ: polyglutamine 
-Syn: -Synuclein 
UPS: ubiquitin proteasome system 
 
 
 
SUPPLEMENTARY MATERIAL 
 
 
Supplementary Figure 1: Immuno-electron microscopy image showing the filamentous 
ultrastructure of a small inclusion in cortex of a HD94 mouse stained with the CAG53b 
anti-N-terminal Htt antibody and developed with a secondary antibody conjugated to 
peroxidase. Thick arrows show filaments with a strong DAB precipitate labeling. 
Magnification: 60000 x. 
 
Supplementary Figure 2: Breeding Protocol. A, Schematic representation of the breeding 
protocol to obtain R6/1 mice with decreased -syn gene dosage. B, Number of 
experimental mice obtained for the whole study. C, Frequencies of the observed and the 
expected number of animals for each genotype is shown.  
 








